Ault Global purchased an aggregate of 295,000 shares of common stock or 9.96% equity interest in NTN Buzztime (NTN) at a weighted average price of $3.42 per share in...
John Wiley & Sons, Inc. JW.A released third-quarter fiscal 2019 results, wherein both the top and bottom line decreased year over year and also fell short of the Zacks...
AMC Networks Inc. (NASDAQ:AMCX) reported fourth-quarter 2018 adjusted earnings of $1.92 per share that beat the Zacks Consensus Estimate of $1.81. The figure also increased 14.3%...
Liberty Global (NASDAQ:LBTYA) reported fourth-quarter 2018 net earnings of $25.1 million, against the year-ago quarter’s loss of $992 million.Revenues on a reported basis...
Brooklyn ImmunoTherapeutics, Inc. (Brooklyn), formerly NTN Buzztime, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on cytokine-based therapies in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Brooklyn is engaged in developing IRX-2, a cytokine-based therapy, to treat patients with head and neck cancer. IRX-2 is an allogeneic, reproducible, primary, human cell-derived Interleukin-2 (IL-2) therapeutic with multiple active cytokine components that act on various parts of the immune system, to activate the entire tumor microenvironment. In addition to IL-2, IRX-2 contains multiple human cytokines that promote or enhance an immune response. IRX-2 is administered as an injection around lymph node beds.